Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,654 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials.
Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, Kyasani M, Manoharan SK, Medigeshi G, Singh J, Shaman H, Singh C, Rao A V. Thuluva S, et al. Among authors: singh j, singh c. EBioMedicine. 2022 Sep;83:104217. doi: 10.1016/j.ebiom.2022.104217. Epub 2022 Aug 12. EBioMedicine. 2022. PMID: 35970020 Free PMC article. Clinical Trial.
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
Medigeshi GR, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S, Das B, Gosain M, Ayushi, Singh J, Anbalagan A, Shaman H, Pargai K, Mehdi F, Das SJ, Kahlon N, Singh S, Kshetrapal P, Wadhwa N, Pandey AK, Bhatnagar S, Garg PK. Medigeshi GR, et al. Among authors: singh j, singh s. EBioMedicine. 2022 Apr;78:103938. doi: 10.1016/j.ebiom.2022.103938. Epub 2022 Mar 16. EBioMedicine. 2022. PMID: 35305396 Free PMC article.
A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant.
Hingankar N, Deshpande S, Das P, Rizvi ZA, Wibmer CK, Mashilo P, Ansari MY, Burns A, Barman S, Zhao F, Mukherjee S, Torres JL, Chattopadhyay S, Mehdi F, Sutar J, Rathore DK, Pargai K, Singh J, Sonar S, Jakhar K, Dandotiya J, Bhattacharyya S, Mani S, Samal S, Singh S, Kshetrapal P, Thiruvengadam R, Batra G, Medigeshi G, Ward AB, Bhatnagar S, Awasthi A, Sok D, Bhattacharya J. Hingankar N, et al. Among authors: singh j, singh s. PLoS Pathog. 2022 Apr 28;18(4):e1010465. doi: 10.1371/journal.ppat.1010465. eCollection 2022 Apr. PLoS Pathog. 2022. PMID: 35482816 Free PMC article.
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla RR, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Narang M, Nanjappa P, Mahantshetti N, Swarup Garg B, Pandey AK. Thuluva S, et al. Among authors: singh j. Vaccine. 2022 Nov 22;40(49):7130-7140. doi: 10.1016/j.vaccine.2022.10.045. Epub 2022 Oct 31. Vaccine. 2022. PMID: 36328879 Clinical Trial.
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.
Parray HA, Narayanan N, Garg S, Rizvi ZA, Shrivastava T, Kushwaha S, Singh J, Murugavelu P, Anantharaj A, Mehdi F, Raj N, Singh S, Dandotiya J, Lukose A, Jamwal D, Kumar S, Chiranjivi AK, Dhyani S, Mishra N, Kumar S, Jakhar K, Sonar S, Panchal AK, Tripathy MR, Chowdhury SR, Ahmed S, Samal S, Mani S, Bhattacharyya S, Das S, Sinha S, Luthra K, Batra G, Sehgal D, Medigeshi GR, Sharma C, Awasthi A, Garg PK, Nair DT, Kumar R. Parray HA, et al. Among authors: singh j, singh s. PLoS Pathog. 2022 Dec 12;18(12):e1010994. doi: 10.1371/journal.ppat.1010994. eCollection 2022 Dec. PLoS Pathog. 2022. PMID: 36508467 Free PMC article.
Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth.
Deshpande S, Ansari MY, Sutar J, Das P, Hingankar N, Mukherjee S, Jayal P, Singh S, Anantharaj A, Singh J, Chattopadhyay S, Raghavan S, Gosain M, Chauhan S, Shrivas S, Prasad C, Chauhan S, Sharma N, Jana P, Thiruvengadam R, Kshetrapal P, Wadhwa N, Das B, Batra G, Medigeshi G, Sok D, Bhatnagar S, Garg PK, Bhattacharya J. Deshpande S, et al. Among authors: singh j, singh s. Microbiol Spectr. 2023 Mar 22;11(2):e0433222. doi: 10.1128/spectrum.04332-22. Online ahead of print. Microbiol Spectr. 2023. PMID: 36946746 Free PMC article.
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Singh C, Rao A V, Basu I, Kumar KAA, Pandey AK. Thuluva S, et al. Among authors: singh j, singh c. Hum Vaccin Immunother. 2023 Dec 31;19(1):2203632. doi: 10.1080/21645515.2023.2203632. Epub 2023 Apr 27. Hum Vaccin Immunother. 2023. PMID: 37113012 Free PMC article. Clinical Trial.
Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis.
Manak M, Gagnon L, Phay-Tran S, Levesque-Damphousse P, Fabie A, Daugan M, Khan ST, Proud P, Hussey B, Knott D, Charlton S, Hallis B, Medigeshi GR, Garg N, Anantharaj A, Raqib R, Sarker P, Alam MM, Rahman M, Murreddu M, Balgobind A, Hofman R, Grappi S, Coluccio R, Calandro P, Montomoli E, Mattiuzzo G, Prior S, Le Duff Y, Page M, Mitchell J, Schwartz LM, Bartsch YC, Azizi A, Bernasconi V; CEPI CLN Study Group. Manak M, et al. Lancet Microbe. 2024 Mar;5(3):e216-e225. doi: 10.1016/S2666-5247(23)00324-5. Epub 2024 Jan 23. Lancet Microbe. 2024. PMID: 38278167 Free article.
8,654 results